Vedolizumab for the treatment of ulcerative colitis and Crohns disease

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 883-898

  McLean, Leon P ^a,b   Shea Donohue, Terez ^a,b   Cross, Raymond K ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

47 antagonist; cell adhesion molecule inhibitor; Crohns disease; inflammatory bowel disease; LDP 02; MLN 00002; MLN 02; natalizumab; ulcerative colitisn vedolizumab

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; NATALIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VEDOLIZUMAB;

ABDOMINAL PAIN; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; CATHETER INFECTION; COLON RESECTION; COMPRESSION FRACTURE; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DRUG BINDING SITE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ESOPHAGOGASTRODUODENOSCOPY; FATIGUE; FLOW CYTOMETRY; FOLLOW UP; GASTROENTERITIS; HUMAN; HYPERTENSION; ILEOANAL ANASTOMOSIS; IMMUNOHISTOCHEMISTRY; INFUSION RELATED REACTION; INJECTION SITE REACTION; KIDNEY FAILURE; LIVER FUNCTION TEST; LOBAR PNEUMONIA; LUPUS LIKE SYNDROME; LYMPHOCYTE COUNT; LYMPHOMA; MAINTENANCE DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; OPPORTUNISTIC INFECTION; PARESTHESIA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSORIASIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VOMITING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG AND NARCOTIC CONTROL; HUMANS;

EID: 84867359637     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.85     Document Type: Article

References (70)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126(6), 1504-1517 (2004). (Pubitemid 38649869)
2. Molodecky NA, Soon IS, Rabi DM et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1), 46-54.e42; quiz e30 (2012).
3. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12(Suppl. 1), S3-S9 (2006). (Pubitemid 43068428)
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448(7152), 427-434 (2007). (Pubitemid 47123518)
5. Satsangi J, Jewell DP, Rosenberg WM, Bell JI. Genetics of inflammatory bowel disease. Gut 35(5), 696-700 (1994). (Pubitemid 24163802)
6. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm. Bowel Dis. 17(7), 1603-1609 (2011).
7. Kappelman MD, Rifas-Shiman SL, Porter CQ et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology 135(6), 1907-1913 (2008).
8. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J. Pharmacol. Exp. Ther. 330(3), 864-875 (2009).
9. Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40(Suppl. 2), S253-S259 (2008). (Pubitemid 351878068)
10. Jess T, Riis L, Vind I et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm. Bowel Dis. 13(4), 481-489 (2007). (Pubitemid 46668255)
11. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease. Systematic review and meta-analysis. Am. J. Gastroenterol. 106(4), 644-659; quiz 660 (2011).
12. Leung Y, Panaccione R. Anti-adhesion molecule strategies for Crohn disease. BioDrugs 22(4), 259-264 (2008). (Pubitemid 351969833)
13. Ben-Horin S, Chowers Y. Review article. Loss of response to anti-TNF treatments in Crohn's disease. Aliment. Pharmacol. Ther. 33(9), 987-995 (2011).
14. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn's disease. Br. J. Surg. 87(12), 1697-1701 (2000).
15. Colombel JF, Sandborn WJ, Reinisch W et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362(15), 1383-1395 (2010).
16. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 130(3), 650-656 (2006). (Pubitemid 43374514)
17. Barreiro O, Sanchez-Madrid F. Molecular basis of leukocyte-endothelium interactions during the inflammatory response. Rev. Esp. Cardiol. 62(5), 552-562 (2009).
18. Agace WW. Tissue-tropic effector T cells: generation and targeting opportunities. Nat. Rev. Immunol. 6(9), 682-692 (2006). (Pubitemid 44298217)
19. Matsuzaki K, Tsuzuki Y, Matsunaga H et al. In vivo demonstration of T lymphocyte migration and amelioration of ileitis in intestinal mucosa of SAMP1/Yit mice by the inhibition of MAdCAM-1. Clin. Exp. Immunol. 140(1), 22-31 (2005). (Pubitemid 40461069)
20. Targan SR, Feagan BG, Fedorak RN et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology 132(5), 1672-1683 (2007). (Pubitemid 46695722)
21. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353(18), 1912-1925 (2005). (Pubitemid 41565956)
22. Kuehn BM. Rare neurological condition linked to newer monoclonal antibody biologics. JAMA 301(14), 1423-1424 (2009).
23. TYSABRI®, prescribing information. Biogen Idec Inc., MA, USA (2012).
24. Hunt D, Giovannoni G. Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring. Pract. Neurol. 12(1), 25-35 (2012).
25. Milch C, Wyant T, Xu J, Kent W, Berger J, Fox I. Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. Presented at: 19th United European Gastroenterology Week. Stockholm, Sweden, 22-26 October 2011.
26. Fedyk E, Csizmadia V, Shyu W, Yang L, Wyant T, Kadambi V. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates. Inflamm. Bowel Dis. 17(Suppl. 1), S4-S5 (2011).
27. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap. Adv. Gastroenterol. 4(4), 237-248 (2011).
28. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst. Rev. 1, CD003715 (2005).
29. Pithadia AB, Jain S. Treatment of inflammatory bowel disease (IBD). Pharmacol. Rep. 3(3), 629-642 (2011).
30. Lim WC, Hanauer S. Aminosalicylates for induction of remission or response in Crohn's disease. Cochrane Database Syst. Rev. 12, CD008870 (2010).
31. Summers RW, Switz DM, Sessions JT Jr et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 77(4 Pt 2), 847-869 (1979). (Pubitemid 9242048)
32. Peyrin-Biroulet L, Lemann M. Review article: remission rates achievable by current therapies for inflammatory bowel disease. Aliment. Pharmacol. Ther. 33(8), 870-879 (2011).
33. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54(8), 1121-1125 (2005). (Pubitemid 41025906)
34. Sternthal MB, Murphy SJ, George J, Kornbluth A, Lichtiger S, Present DH. Adverse events associated with the use of cyclosporine in patients with inflammatory bowel disease. Am. J. Gastroenterol. 103(4), 937-943 (2008). (Pubitemid 351501092)
35. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1, CD003459 (2005).
36. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332(5), 292-297 (1995).
37. Wahed M, Louis-Auguste JR, Baxter LM et al. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 30(6), 614-620 (2009).
38. Carbonnel F. Methotrexate. A drug of the future in ulcerative colitis? Curr. Drug Targets 12(10), 1413-1416 (2011).
39. Rutgeerts P, Sandborn WJ, Feagan BG et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353(23), 2462-2476 (2005). (Pubitemid 41770166)
40. Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337(15), 1029-1035 (1997).
41. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359(9317), 1541-1549 (2002). (Pubitemid 34621118)
42. Sands BE, Blank MA, Patel K, Van Deventer SJ. Long-term treatment of rectovaginal fistulas in Crohn's disease: response to infliximab in the ACCENT II Study. Clin. Gastroenterol. Hepatol. 2(10), 912-920 (2004). (Pubitemid 39335798)
43. Colombel JF, Sandborn WJ, Rutgeerts P et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am. J. Gastroenterol. 104(5), 1170-1179 (2009).
44. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn's disease. N. Engl. J. Med. 357(3), 228-238 (2007). (Pubitemid 47080387)
45. Feagan BG, Sandborn WJ, Wolf DC et al. Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn's disease with prior loss of response to infliximab. Aliment. Pharmacol. Ther. 33(5), 541-550 (2011).
46. Afif W, Loftus EV Jr, Faubion WA et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am. J. Gastroenterol. 105(5), 1133-1139 (2010).
47. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann. Rheum. Dis. 68(11), 1739-1745 (2009).
48. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348(7), 601-608 (2003). (Pubitemid 36204954)
49. de Vries HS, van Oijen MG, Driessen RJ et al. Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists. Br. J. Clin. Pharmacol. 71(1), 7-19 (2011).
50. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54(7), 2136-2146 (2006). (Pubitemid 44051069)
51. Fleischmann R, Vencovsky J, van Vollenhoven RF et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann. Rheum. Dis. 68(6), 805-811 (2009).
52. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B. Hospitalisations and surgery in Crohn's disease. Gut 61(4), 622-629 (2012).
53. Whelan G, Farmer RG, Fazio VW, Goormastic M. Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology 88(6), 1826-1833 (1985). (Pubitemid 15052294)
54. Briskin M, Winsor-Hines D, Shyjan A et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151(1), 97-110 (1997). (Pubitemid 27283962)
55. Yu Y, Zhu J, Mi LZ et al. Structural specializations of alpha(4)beta(7), an integrin that mediates rolling adhesion. J. Cell Biol. 196(1), 131-146 (2012).
56. WHO. International nonproprietary names for pharmaceutical substances. WHO Drug Information 22(4), 311-367 (2008).
57. Hesterberg PE, Winsor-Hines D, Briskin MJ et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 111(5), 1373-1380 (1996). (Pubitemid 26362264)
58. Feagan BG, Greenberg GR, Wild G et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. 352(24), 2499-2507 (2005). (Pubitemid 41007865)
59. Parikh A, Leach T, Wyant T et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled Phase 2 dose-ranging study. Inflamm. Bowel Dis. 18(8), 1470-1479 (2012).
60. Feagan BG, Greenberg GR, Wild G et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol. 6(12), 1370-1377 (2008).
61. Feagan B, Rutgeerts P, Sands B et al. Vedolizumab induction therapy for ulcerative colitis: results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter Phase 3 trial. Gastroenterology 142(5), S160-S161 (2012).
62. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 3(1), 76-99 (2011).
63. Parikh A, Wyant T, Clifford D et al. No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic cells after treatment with vedolizumab, a humanized monoclonal antibody to a4b7 integrin. Gastroenterology 138(5), S145-S146 (2010).
64. Fiorino G, Correale C, Fries W, Repici A, Malesci A, Danese S. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease. Expert Rev. Clin. Immunol. 6(4), 567-572 (2010).
65. Feagan BG, McDonald JW, Greenberg GR et al. An ascending dose trial of a humanized A4B7 antibody in ulcerative colitis. Gastroenterology 118, A874 (2000).
66. Thomas S, Baumgart DC. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology 20(1), 1-18 (2011).
67. Rutgeerts P, Fedorak RN, Homme DW et al. A Phase I study of rHuMab Beta7 in moderate to severe ulcerative colitis (UC). Gastroenterology 140, S125 (2011).
68. Takazoe M, Watanabe M, Kawaguchi T et al. Oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn's disease-a randomized, double-blind, placebo-controlled trial. Gastroenterology 136, A180 (2009).
69. Monteleone G, Pallone F, MacDonald TT. Emerging immunological targets in inflammatory bowel disease. Curr. Opin Pharmacol. 11(6), 640-645 (2011).
70. Vermeire S, Ghosh S, Panes J et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 60(8), 1068-1075 (2011).